Back in September, The New York Times published an article about Turig Pharmaceuticals raising the price of the drug Deraprim by 5000 percent per tablet and the nefarious price-gouging chief executive behind that decision, Martin Shkreli. Deraprim is typically used to treat infections in people with compromised immune systems, like cancer patients and those who […]
Back in September, The New York Times published an article about Turig Pharmaceuticals raising the price of the drug Deraprim by 5000 percent per tablet and the nefarious price-gouging chief executive behind that decision, Martin Shkreli. Deraprim is typically used to treat infections in people with compromised immune systems, like cancer patients and those who […]
Share this Article
Recommended